安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | For HCP
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors
- Adstiladrin: Uses, Dosage, Side Effects Warnings - Drugs. com
Adstiladrin (nadofaragene firadenovec-vncg) is a prescription gene therapy used to treat certain adults with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) It works by delivering the interferon alfa-2b gene into cells in the bladder wall
- ADSTILADRIN | FDA
ADSTILADRIN is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS
- Nadofaragene firadenovec - Wikipedia
Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy for the treatment of bladder cancer [1][3][4] It is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy
- U. S. FDA Approves Label Update to Accelerate Thaw Time for ADSTILADRIN . . .
ADSTILADRIN is the first and only FDA-approved non-replicating intravesical gene-therapy for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without papillary tumors (±Ta T1)
- ADSTILADRIN® (nadofaragene firadenovec-vncg) | NMIBC Treatment
ADSTILADRIN is the first and only FDA-approved gene therapy for treating adult patients with high-risk BCG-unresponsive NMIBC See Important Safety Info
- Ferring announces full availability of ADSTILADRIN® (nadofaragene . . .
Approved by the U S Food Drug Administration (FDA) in December 2022, ADSTILADRIN is the first and only FDA-approved intravesical gene therapy for adults with NMIBC who no longer respond to standard therapy
- Nadofaragene firadenovec-vncg (urinary bladder route)
Appropriate studies have not been performed on the relationship of age to the effects of Adstiladrin® in the pediatric population Safety and efficacy have not been established
|
|
|